Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EXELIXIS, INC. Director's Dealing 2019

Mar 28, 2019

30561_dirs_2019-03-27_5fea9e73-21b5-463c-a0ee-88c452e2b993.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2019-03-26

Reporting Person: Haley Patrick J. (Sr. Vice President, Commercial)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-03-26 Common Stock M 2700 $5.18 Acquired 92480 Direct
2019-03-26 Common Stock S 2700 $23.47 Disposed 89780 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-03-26 Option (right to buy) $5.18 M 2700 Disposed 2019-03-29 Common Stock (2700.0) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 23539 Indirect
Common Stock 10648 Indirect

Footnotes

F1: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2018.

F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.33 to $23.63. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

F4: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of March 25, 2019.

F5: The option, representing the right to purchase a total of 2,700 shares of Exelixis, Inc. common stock, became fully exercisable on March 30, 2016.